Literature DB >> 20026405

Leukemia stem cells.

Steven W Lane1, D Gary Gilliland.   

Abstract

Leukemia stem cells (LSC) reside within a hierarchy of malignant hematopoiesis and possess the ability to instigate, maintain and serially propagate leukemia in vivo, while retaining the capacity to differentiate into committed progeny that lack these properties. In most cases, LSC appear to share immunophenotypic characteristics with committed hematopoietic progenitors, however have pathologically enhanced self-renewal, mediated through the activation of certain cellular pathways. The presence of a LSC that solely possesses the ability to initiate and sustain leukemia has implications for the treatment of patients with this disease. In this review, we will discuss these issues as well as some of the recent controversies regarding LSC frequency and alternative theories of leukemogenesis.

Entities:  

Mesh:

Year:  2009        PMID: 20026405     DOI: 10.1016/j.semcancer.2009.12.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  22 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

2.  Acute myeloid leukemia stem cell function is preserved in the absence of autophagy.

Authors:  Amy H Porter; Lucie Leveque-El Mouttie; Therese Vu; Claudia Bruedigam; Joanne Sutton; Sebastien Jacquelin; Geoffrey R Hill; Kelli P A MacDonald; Steven W Lane
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

3.  Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells

Authors:  Mahdieh Salemi; Saeed Mohammadi; Ardeshir Ghavamzadeh; Mohsen Nikbakht
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

Review 4.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

5.  Mathematical model of adult stem cell regeneration with cross-talk between genetic and epigenetic regulation.

Authors:  Jinzhi Lei; Simon A Levin; Qing Nie
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-05       Impact factor: 11.205

6.  Differential niche and Wnt requirements during acute myeloid leukemia progression.

Authors:  Steven W Lane; Yingzi J Wang; Cristina Lo Celso; Christine Ragu; Lars Bullinger; Stephen M Sykes; Francesca Ferraro; Sebastian Shterental; Charles P Lin; D Gary Gilliland; David T Scadden; Scott A Armstrong; David A Williams
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

Review 7.  Survival regulation of leukemia stem cells.

Authors:  Yiguo Hu; Shaoguang Li
Journal:  Cell Mol Life Sci       Date:  2015-12-19       Impact factor: 9.261

8.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

9.  Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.

Authors:  R B Walter; G S Laszlo; J M Lionberger; J A Pollard; K H Harrington; C J Gudgeon; M Othus; S Rafii; S Meshinchi; F R Appelbaum; I D Bernstein
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

Review 10.  Stem-like cells and therapy resistance in squamous cell carcinomas.

Authors:  Nicole Facompre; Hiroshi Nakagawa; Meenhard Herlyn; Devraj Basu
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.